ANALYTICAL/QUALITY ARTICLES
-
![genetic engineering and gene manipulation, CRISPR technology, genome editing, molecular biotechnology, genetic science research, gene therapy-GettyImages-2196575232]( "From Supporting Component to Strategic Driver: The Evolving Role of gRNA in CRISPR Therapeutics")
From Supporting Component to Strategic Driver: The Evolving Role of gRNA in CRISPR TherapeuticsGuide RNA is evolving from a simple targeting reagent into a complex, engineered molecule shaped by expanding CRISPR modalities, increasing length and modification demands, and tighter integration with manufacturability, analytical control, and regulatory expectations.
-
![Business support, teamwork-GettyImages-2267605245]( "The RNA Ties That Bind: 3 Takeaways From The OPT Congress")
The RNA Ties That Bind: 3 Takeaways From The OPT CongressHere, I unpack three takeaways I had from the OPT Congress, each of which I’d argue are indicative of the interconnectedness across the genetic medicines field.
-
![Test Tubes-GettyImages-139700261]( "Rethinking ATMP Assurance When Sterility Timelines, Reality Misalign")
Rethinking ATMP Assurance When Sterility Timelines, Reality MisalignThe compendial 14-day sterility testing window exposes product and patient to numerous risks, but settling on a rapid alternative also presents its own set of challenges.
-
![Liver Pop Art-GettyImages-531038489]( "MicroRNA Therapeutics In Metabolic Liver Disease: Context-Driven Drug Discovery")
MicroRNA Therapeutics In Metabolic Liver Disease: Context-Driven Drug DiscoveryRealizing the therapeutic potential of miRNAs in liver disease requires confronting a problem the field has not fully reckoned with.
-
![Game Strategy-GettyImages-169983235]( "Inside Alnylam's Playbook For High Volume siRNA Production")
Inside Alnylam's Playbook For High Volume siRNA ProductionAs one of the first companies to establish a chemoenzymatic ligation platform, Alnylam's Maines and Nechev are in the perfect position to espouse wisdom on the practical aspects and remaining challenges of implementing enzymatic ligation at a large scale. Here in this installment, Maines and Nechev outline what they’ve learned thus far about the science of enzymatic ligation, while also paying credence to the unknowns and existing barriers that, as a frontrunner, Alnylam will inevitably (but willingly) be tasked with facing in the future.
-
![Protein ribbon structure-GettyImages-2192885402]( "Proteomics Tools: A Resurrection")
Proteomics Tools: A ResurrectionFor decades, the evolution of proteomics has lagged. Now, a resurrection is underway. New tools are dismantling limitations, signifying a maturation of systems biology.
ANALYTICAL/QUALITY VIDEOS
Endoribonuclease-prepared siRNAs (esiRNAs) are able to overcome the limitations of RNAi. Learn about esiRNAs, their advantages over standard siRNAs, and ways this technology is utilized in different research fields.
As CRISPR technology evolves beyond the original Cas9, gRNAs are transitioning from simple targeting tools into highly engineered, complex molecules. In this Advancing RNA Live segment, speakers April Sena, Max De Long, and Venkat Krishnamurthy discuss how the rise of diverse nucleases — including prime editors — is impacting gRNA synthesis and purity.
Linear mRNA analytical development has been rapidly advancing in the past few years and this panel discussion explores some of the biggest changes we’ve seen in the linear mRNA analytical paradigm.
Here, Ethris’ Christan Dohmen and Tune Therapeutics’ Stu Sundseth share their take on the most meaningful strategies for reducing dsRNA production. But this discussion also probes a deeper question: Is dsRNA still the most relevant impurity the industry should be chasing, or should focus shift to other contaminants?
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1209059816 assay]( "Understanding RNA Higher-Order Structure Dynamics For CRISPR Applications")
Understanding RNA Higher-Order Structure Dynamics For CRISPR ApplicationsScientists are gaining valuable knowledge about the structural dynamics of guide RNAs used in CRISPR-Cas9. This deeper understanding could pave the way for improved gene editing tools.
-
![GettyImages-1493793527 lab, pipette, research]( "Development Of Alternative BCDP Reagents For The Synthesis Of 5' -Terminal Phosphate Oligonucleotides")
Development Of Alternative BCDP Reagents For The Synthesis Of 5' -Terminal Phosphate OligonucleotidesNew alternative phosphitylating reagents reduce the safety hazards associated with BCDP, enabling a safer and effective synthesis of key oligonucleotide sequences.
-
![Gett images-542576580 bio]( "Top 5 Approaches To The Bioanalysis Of Oligonucleotides")
Top 5 Approaches To The Bioanalysis Of OligonucleotidesEvaluate the strengths and limitations of each bioanalysis method carefully to choose the most effective strategy for your clinical study.
-
![Lipid Nanoparticle mRNA Vaccine GettyImages-1418152448]( "Lipid Nanoparticle Compositional Analysis By UHPLC-CAD")
Lipid Nanoparticle Compositional Analysis By UHPLC-CADExplore results generated from an internal study using a proprietary mRNA-LNP formulation and UHPLC-CAD, a powerful technique for the analysis of compounds that do not contain chromophores.
-
![Thermo Fisher - Peptones]( "The Value Of Peptones For Enhancing Biopharmaceutical Productivity")
The Value Of Peptones For Enhancing Biopharmaceutical ProductivityPeptones, versatile media additives derived from various sources, offer numerous benefits for biopharmaceutical production.
-
![GettyImages-1209614664-cell-gene-dna-research-development]( "Quantification Of Large Oligonucleotides Using High Resolution MS/MS")
Quantification Of Large Oligonucleotides Using High Resolution MS/MSExplore how to achieve sensitive, high-resolution analysis of large oligonucleotides, with the opportunity to perform both qualitative and quantitative analysis in a single run.
-
![exam, test, analysis, innovation, development-GettyImages-2149039471]( "Why Bioanalysis Needs To Break Free From Manual Bottlenecks")
Why Bioanalysis Needs To Break Free From Manual BottlenecksBioanalysis remains one of the most persistent bottlenecks in drug development, with CROs displaying inefficiencies that are no longer operational nuisances but strategic liabilities.
